Publication date: December 2026 Source: The Journal of Prevention of Alzheimer's Disease, Volume 13, Issue 10 Author(s): Lisa Le Scouarnec, Vincent Bouteloup, Leslie Grasset, Vincent Planche, Geneviève Chêne, Carole Dufouil, Michèle Allard, Sara Amroun, Katia Andrade, Marion Andro, Daniela Andruita, Mariam Annan, Cédric Annweiler, Pierre Anthony, Marine Asfar, Christine Astier, Alexandre Augier, Nicolas Auguste, Sophie Auriacombe, Clément Aveneau
Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France. // The Journal of Prevention of Alzheimer's Disease. – URL: https://www.sciencedirect.com/science/article/pii/S2274580726002062?dgcid=rss_sd_all
Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France. The Journal of Prevention of Alzheimer's Disease. https://www.sciencedirect.com/science/article/pii/S2274580726002062?dgcid=rss_sd_all
“Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France.” The Journal of Prevention of Alzheimer's Disease.
@article{article68271,
title = {Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France},
journal = {The Journal of Prevention of Alzheimer's Disease},
url = {https://www.sciencedirect.com/science/article/pii/S2274580726002062?dgcid=rss_sd_all}
}